A Phase 1 Study of the Safety and Tolerability of CTX-10726 | MicrobiomeTrials← Back to trialsNCT07419841
A Phase 1 Study of the Safety and Tolerability of CTX-10726
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2026-05-28Est. Completion: 2028-04-01
Enrollment target: 70 participants Locations- Mayo Clinic Arizona, Phoenix, Arizona, United States
- Mayo Clinic Florida, Jacksonville, Florida, United States
- Mayo Clinic Rochester, Rochester, Minnesota, United States
- Nebraska Cancer Specialists, Omaha, Nebraska, United States
- START New York, Lake Success, New York, United States
- UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
- Prisma Health Cancer Institute, Greenville, South Carolina, United States
- SCRI Oncology Partners, Nashville, Tennessee, United States
Other microbiome trials you might be interested in
Solid TumorsGastric CancerNon-Small Cell Lung Cancer (NSCLC)Pancreatic CancerPancreatic Ductal Adenocarcinoma (PDAC)
The PROCEADE PanTumor study aims to investigate M9140 in multiple tumor types which express carcinoembryonic antigen-rel…
Santa Monica, United StatesEst. completion Dec 23, 2027
Gastric CancerGastric AdenocarcinomaGastric (Stomach) CancerGastroesophageal Adenocarcinoma
Gastroesophageal Cancer (GC)
Gastroesophageal Junction (GEJ) Adenocarcinoma
Gastroesophageal Junction (GEJ) Cancer
Gastrointestinal Cancer Metastatic
Gastrointestinal Adenocarcinoma
Gastrointestinal Cancers
Colorectal (Colon or Rectal) Cancer
Pancreatic Cancer
CDH17-positive Advanced Solid Tumors
Advanced Gastric Cancer
This study is looking at how safe BHB810 is in adults with gastric and gastroesophageal adenocarcinoma (GEJ). The purpos…
Duarte, United StatesEst. completion Dec 2028